|
1
|
Ricketts CJ and Linehan WM: Multi-regional
sequencing elucidates the evolution of clear cell renal cell
carcinoma. Cell. 173:540–542. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bharthuar A, Pandey H and Sood S:
Management of metastatic renal cell carcinoma-mini review. J Kidney
Cancer VHL. 2:75–83. 2015. View Article : Google Scholar
|
|
3
|
Boguslawska J, Kryst P, Poletajew S and
Piekielko-Witkowska A: TGF-β and microRNA interplay in
genitourinary cancers. Cells. 8:16192019. View Article : Google Scholar
|
|
4
|
Bihr S, Ohashi R, Moore AL, Rüschoff JH,
Beisel C, Hermanns T, Mischo A, Corrò C, Beyer J, Beerenwinkel N,
et al: Expression and mutation patterns of PBRM1, BAP1 and SETD2
mirror specific evolutionary subtypes in clear cell renal cell
carcinoma. Neoplasia. 21:247–256. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Brugarolas J: Molecular genetics of
clear-cell renal cell carcinoma. J Clin Oncol. 32:1968–1976. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Boguslawska J, Poplawski P, Alseekh S,
Koblowska M, Iwanicka-Nowicka R, Rybicka B, Kędzierska H,
Głuchowska K, Hanusek K, Tański Z, et al: MicroRNA-mediated
metabolic reprograming in renal cancer. Cancers (Basel).
11:18252019. View Article : Google Scholar
|
|
7
|
Schanza LM, Seles M, Stotz M, Fosselteder
J, Hutterer GC, Pichler M and Stiegelbauer V: MicroRNAs associated
with Von Hippel-Lindau pathway in renal cell carcinoma: A
comprehensive review. Int J Mol Sci. 18:24952017. View Article : Google Scholar
|
|
8
|
Stuelten CH and Zhang YE: Transforming
growth factor-β: An agent of change in the tumor microenvironment.
Front Cell Dev Biol. 9:7647272021. View Article : Google Scholar
|
|
9
|
Bogusławs ka J, Rodzik K, Popławski P,
Kędzierska H, Rybicka B, Sokół E, Tański Z and Piekiełko-Witkowska
A: TGF-β1 targets a microRNA network that regulates cellular
adhesion and migration in renal cancer. Cancer Lett. 412:155–169.
2018. View Article : Google Scholar
|
|
10
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
11
|
Lu TP, Lee CY, Tsai MH, Chiu YC, Hsiao CK,
Lai LC and Chuang EY: miRSystem: An integrated system for
characterizing enriched functions and pathways of microRNA targets.
PLoS One. 7:e423902012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li JH, Liu S, Zhou H, Qu LH and Yang JH:
starBase v2.0: Decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA
interaction networks from large-scale CLIP-Seq data. Nucleic Acids
Res. 42:D92–D97. 2014. View Article : Google Scholar
|
|
13
|
Chen F, Chandrashekar DS, Varambally S and
Creighton CJ: Pan-cancer molecular subtypes revealed by
mass-spectrometry-based proteomic characterization of more than 500
human cancers. Nat Commun. 10:56792019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yang L, Zou X, Zou J and Zhang G: A review
of recent research on the role of MicroRNAs in renal cancer. Med
Sci Monit. 27:e9306392021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Spadaccino F, Gigante M, Netti GS,
Rocchetti MT, Franzin R, Gesualdo L, Castellano G, Stallone G and
Ranieri E: The ambivalent role of miRNAs in carcinogenesis:
Involvement in renal cell carcinoma and their clinical
applications. Pharmaceuticals (Basel). 14:3222021. View Article : Google Scholar
|
|
16
|
Sun IO and Lerman LO: Urinary microRNA in
kidney disease: Utility and roles. Am J Physiol Renal Physiol.
316:F785–F793. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Morizane R, Fujii S, Monkawa T, Hiratsuka
K, Yamaguchi S, Homma K and Itoh H: miR-34c attenuates
epithelial-mesenchymal transition and kidney fibrosis with ureteral
obstruction. Sci Rep. 4:45782014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Boguslawska J, Kedzierska H, Poplawski P,
Rybicka B, Tanski Z and Piekielko-Witkowska A: Expression of genes
involved in cellular adhesion and extracellular matrix remodeling
correlates with poor survival of patients with renal cancer. J
Urol. 195:1892–1902. 2016. View Article : Google Scholar
|
|
19
|
Wang R, Ma Y, Yu D, Zhao J and Ma P:
miR-377 functions as a tumor suppressor in human clear cell renal
cell carcinoma by targeting ETS1. Biomed Pharmacother. 70:64–71.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Toschi A, Edelstein J, Rockwell P, Ohh M
and Foster DA: HIF alpha expression in VHL-deficient renal cancer
cells is dependent on phospholipase D. Oncogene. 27:2746–2753.
2008. View Article : Google Scholar
|
|
21
|
Ferro E, Enrico Bena C, Grigolon S and
Bosia C: From endogenous to synthetic microRNA-mediated regulatory
circuits: An overview. Cells. 8:15402019. View Article : Google Scholar
|
|
22
|
Majo S, Courtois S, Souleyreau W, Bikfalvi
A and Auguste P: Impact of extracellular matrix components to renal
cell carcinoma behavior. Front Oncol. 10:6252020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Micucci C, Matacchione G, Valli D, Orciari
S and Catalano A: HIF2α is involved in the expansion of
CXCR4-positive cancer stem-like cells in renal cell carcinoma. Br J
Cancer. 113:1178–1185. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shinojima T, Oya M, Takayanagi A, Mizuno
R, Shimizu N and Murai M: Renal cancer cells lacking hypoxia
inducible factor (HIF)-1alpha expression maintain vascular
endothelial growth factor expression through HIF-2alpha.
Carcinogenesis. 28:529–536. 2007. View Article : Google Scholar
|
|
25
|
Raval RR, Lau KW, Tran MG, Sowter HM,
Mandriota SJ, Li JL, Pugh CW, Maxwell PH, Harris AL and Ratcliffe
PJ: Contrasting properties of hypoxia-inducible factor 1 (HIF-1)
and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol
Cell Biol. 25:5675–5686. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Melendéz-Rodriguez F, Roche O,
Sanchez-Prieto R and Aragones J: Hypoxia-inducible factor
2-dependent pathways driving Von Hippel-Lindau-deficient renal
cancer. Front Oncol. 8:2142018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mallikarjuna P, Raviprakash TS, Aripaka K,
Ljungberg B and Landström M: Interactions between TGF-β type I
receptor and hypoxia-inducible factor-alpha mediates a synergistic
crosstalk leading to poor prognosis for patients with clear cell
renal cell carcinoma. Cell Cycle. 18:2141–2156. 2019. View Article : Google Scholar
|
|
28
|
Katoh M and Katoh M: Integrative genomic
analyses of ZEB2: Transcriptional regulation of ZEB2 based on
SMADs, ETS1, HIF1alpha, POU/OCT, and NF-kappaB. Int J Oncol.
34:1737–1742. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Dittmer J: The biology of the Ets1
proto-oncogene. Mol Cancer. 2:292003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Taveirne S, Wahlen S, Van Loocke W,
Kiekens L, Persyn E, Van Ammel E, De Mulder K, Roels J, Tilleman L,
Aumercier M, et al: The transcription factor ETS1 is an important
regulator of human NK cell development and terminal
differentiation. Blood. 136:288–298. 2020.PubMed/NCBI
|
|
31
|
Morrell NW: Pulmonary hypertension due to
BMPR2 mutation: A new paradigm for tissue remodeling? Proc Am
Thorac Soc. 3:680–686. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Han R, Beppu H, Lee YK, Georgopoulos K,
Larue L, Li E, Weiner L and Brissette JL: A pair of transmembrane
receptors essential for the retention and pigmentation of hair.
Genesis. 50:783–800. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Burocchi A, Pittoni P, Tili E, Rigoni A,
Costinean S, Croce CM and Colombo MP: Regulated expression of
miR-155 is required for iNKT cell development. Front Immunol.
6:1402015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhu N, Zhang D, Chen S, Liu X, Lin L,
Huang X, Guo Z, Liu J, Wang Y, Yuan W and Qin Y: Endothelial
enriched microRNAs regulate angiotensin II-induced endothelial
inflammation and migration. Atherosclerosis. 215:286–293. 2011.
View Article : Google Scholar
|
|
35
|
Wen P, Cao H, Fang L, Ye H, Zhou Y, Jiang
L, Su W, Xu H, He W, Dai C and Yang J: miR-125b/Ets1 axis regulates
transdifferentiation and calcification of vascular smooth muscle
cells in a high-phosphate environment. Exp Cell Res. 322:302–312.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Renou L, Boelle PY, Deswarte C, Deswarte
C, Spicuglia S, Benyoucef A, Calvo J, Uzan B, Belhocine M, Cieslak
A, et al: Homeobox protein TLX3 activates miR-125b expression to
promote T-cell acute lymphoblastic leukemia. Blood Adv. 1:733–747.
2017. View Article : Google Scholar
|
|
37
|
Zeng JF, Zeng ZL, Zhang K, Zhao Y, Liu YM,
Chen JJ, Tong H, Wei DH, Jiang ZS and Wang Z: miR-23b-3p and
miR-125b-5p downregulate apo(a) expression by targeting Ets1 in
HepG2 cells. Cell Biol Int. 42:313–323. 2018. View Article : Google Scholar
|
|
38
|
Zhang Y, Yan LX, Wu QN, Du ZM, Chen J,
Liao DZ, Huang MY, Hou JH, Wu QL, Zeng MS, et al: miR-125b is
methylated and functions as a tumor suppressor by regulating the
ETS1 proto-oncogene in human invasive breast cancer. Cancer Res.
71:3552–3562. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Geisinger MT, Astaiza R, Butler T, Popoff
SN, Planey SL and Arnott JA: Ets-1 is essential for connective
tissue growth factor (CTGF/CCN2) induction by TGF-beta1 in
osteoblasts. PLoS One. 7:e352582012. View Article : Google Scholar
|
|
40
|
Katabami K, Mizuno H, Sano R, Saito Y,
Ogura M, Itoh S and Tsuji T: Transforming growth factor-beta1
upregulates transcription of alpha3 integrin gene in hepatocellular
carcinoma cells via Ets-transcription factor-binding motif in the
promoter region. Clin Exp Metastasis. 22:539–548. 2005. View Article : Google Scholar
|
|
41
|
Oida T and Weiner HL: Depletion of TGF-β
from fetal bovine serum. J Immunol Methods. 362:195–198. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Bisserier M, Katz MG, Bueno-Beti C,
Brojakowska A, Zhang S, Gubara S, Kohlbrenner E, Fazal S, Fargnoli
A, Dorfmuller P, et al: Combination therapy with STAT3 inhibitor
enhances SERCA2a-induced BMPR2 expression and inhibits pulmonary
arterial hypertension. Int J Mol Sci. 22:91052021. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Assmann J, Leon LG, Stavast CJ, van den
Bogaerdt SE, Schilperoord-Vermeulen J, Sandberg Y, Bellido M,
Erkeland SJ, Feith DJ, Loughran TP Jr and Langerak AW: miR-181a is
a novel player in the STAT3-mediated survival network of
TCRαβ+ CD8+ T large granular lymphocyte
leukemia. Leukemia. Dec 6–2021.Epub ahead of print.
|
|
44
|
Ottaviani S, Stebbing J, Frampton AE,
Zagorac S, Krell J, de Giorgio A, Trabulo SM, Nguyen VT, Magnani L,
Feng H, et al: TGF-β induces miR-100 and miR-125b but blocks let-7a
through LIN28B controlling PDAC progression. Nat Commun.
9:18452018. View Article : Google Scholar
|
|
45
|
Davis BN, Hilyard AC, Nguyen PH, Lagna G
and Hata A: Smad proteins bind a conserved RNA sequence to promote
microRNA maturation by Drosha. Mol Cell. 39:373–384. 2010.
View Article : Google Scholar :
|
|
46
|
Lv SY, Shan TD, Pan XT, Tian ZB, Liu XS,
Liu FG, Sun XG, Xue HG, Li XH, Han Y, et al: The lncRNA ZEB1-AS1
sponges miR-181a-5p to promote colorectal cancer cell proliferation
by regulating Wnt/β-catenin signaling. Cell Cycle. 17:1245–1254.
2018. View Article : Google Scholar
|
|
47
|
Emmrich S, Rasche M, Schoning J, Schöning
J, Reimer C, Keihani S, Maroz A, Xie Y, Li Z, Schambach A, et al:
miR-99a/100~125b tricistrons regulate hematopoietic stem and
progenitor cell homeostasis by shifting the balance between TGFβ
and Wnt signaling. Genes Dev. 28:858–874. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
McCann JV, Xiao L, Kim DJ, Khan OF,
Kowalski PS, Anderson DG, Pecot CV, Azam SH, Parker JS, Tsai YS, et
al: Endothelial miR-30c suppresses tumor growth via inhibition of
TGF-β-induced Serpine1. J Clin Invest. 129:1654–1670. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Bilandzic M and Stenvers KL: Betaglycan: A
multifunctional accessory. Mol Cell Endocrinol. 339:180–189. 2011.
View Article : Google Scholar
|
|
50
|
Nishida J, Miyazono K and Ehata S:
Decreased TGFBR3/betaglycan expression enhances the metastatic
abilities of renal cell carcinoma cells through TGF-β-dependent and
-independent mechanisms. Oncogene. 37:2197–2212. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Dallas NA, Samuel S, Xia L, Fan F, Gray
MJ, Lim SJ and Ellis LM: Endoglin (CD105): A marker of tumor
vasculature and potential target for therapy. Clin Cancer Res.
14:1931–1937. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Hu J, Guan W, Liu P, Dai J, Tang K, Xiao
H, Qian Y, Sharrow AC, Ye Z, Wu L and Xu H: Endoglin is essential
for the maintenance of self-renewal and chemoresistance in renal
cancer stem cells. Stem Cell Reports. 9:464–477. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Zhai W, Li S, Zhang J, Chen Y, Ma J, Kong
W, Gong D, Zheng J, Xue W and Xu Y: Sunitinib-suppressed miR-452-5p
facilitates renal cancer cell invasion and metastasis through
modulating SMAD4/SMAD7 signals. Mol Cancer. 17:1572018. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Hahn AW, Pal SK and Agarwal N: Targeting
endoglin to treat metastatic renal cell carcinoma: Lessons from
osler-weber-rendu syndrome. Oncologist. 24:143–145. 2019.
View Article : Google Scholar
|
|
55
|
Choueiri TK, Michaelson MD, Posadas EM,
Sonpavde GP, McDermott DF, Nixon AB, Liu Y, Yuan Z, Seon BK, Walsh
M, et al: An open label phase Ib dose escalation study of TRC105
(anti-endoglin antibody) with axitinib in patients with metastatic
renal cell carcinoma. Oncologist. 24:202–210. 2019. View Article : Google Scholar
|
